Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareOregon Veppanu Prior Authorization | OpenPayer
    Ask Trek AI about this page
    CurrentCareOregonPolicy N/A

    Veppanu Prior Authorization Guideline

    Customize your policy alerts

    Sign up for all careoregon policy alerts

    Know when careoregon releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This guideline governs initial authorization and reauthorization of Veppanu 100 mg and 200 mg tablets. Coverage requires clinical eligibility, appropriate specialist prescribing, ESR1 mutation documentation, and prior treatment intolerance, failure, or contraindication as specified.

    Policy Summary
    PayerCareOregon
    PolicyVeppanu Prior Authorization Guideline
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of an ESR1 mutation and intolerance, clinical failure, or contraindication to Orserdu or Inluriyo.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsApproval length
    2Tablet strengths covered
    ESR1Required mutation
    2Specialist prescriber types

    Coverage Criteria

    Initial authorization

    Covered when all of the following criteria groups are met.

    • FDA-approved or NCCN-supported use

      • FDA-approved use: Requested drug is FDA-approved for the condition being treated.
      • NCCN-supported use: Treatment is supported for the diagnosis in the NCCN guidelines.
    • Specialist prescriber

      • Hematologist: Prescribed by a hematologist.
    Policy Summary
    PayerCareOregon
    PolicyVeppanu Prior Authorization Guideline
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of an ESR1 mutation and intolerance, clinical failure, or contraindication to Orserdu or Inluriyo.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and DocumentationPolicy BackgroundInitial Therapy CriteriaContinuation and Reauthorization CriteriaStep Therapy Requirement

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Oncologist: Prescribed by an oncologist.
  1. ESR1 mutation: Medical record documentation of an estrogen receptor 1 (ESR1) mutation is provided.
  2. Prior therapy issue

    • Orserdu: Intolerance, clinical failure, or contraindication to Orserdu.
    • Inluriyo: Intolerance, clinical failure, or contraindication to Inluriyo.
  3. Reauthorization

    Reauthorization requires continued clinical benefit.

    Continuation therapy: The patient does not show evidence of progressive disease while on therapy.

    Provider Actions and Documentation

    Prior Authorization

    Prior Authorization Required — Initial Authorization

    Prior authorization is required for Veppanu 100 mg and 200 mg tablets. Initial authorization is limited to 12 months when the applicable approval criteria are met.

    • Requested treatment must be FDA-approved for the condition being treated or supported for the diagnosis in NCCN guidelines.
    • The prescriber must be a hematologist or oncologist.
    Step Therapy

    Prior Therapy Requirement

    Before initial authorization, the member must have documented intolerance, clinical failure, or a contraindication to at least one of the required prior therapies.

    • Orserdu
    • Inluriyo
    Documentation Required

    Required Medical Record Documentation

    Submit medical records supporting the diagnosis and prior-treatment history with the authorization request.

    • Document an estrogen receptor 1 (ESR1) mutation.
    • Document intolerance, clinical failure, or contraindication to Orserdu or Inluriyo.
    Denial Risk

    Failure to Meet Approval Criteria

    Requests may be denied when the use is not FDA-approved or supported by NCCN guidelines, the prescriber does not meet the required specialty qualifications, or the submitted documentation does not establish all approval criteria.

    • Eligible prescriber: hematologist or oncologist.
    • Required approval support: FDA-approved indication or NCCN-supported treatment.
    • Required documentation: ESR1 mutation and intolerance, clinical failure, or contraindication to Orserdu or Inluriyo.
    Denial Risk

    Progressive Disease During Therapy

    For reauthorization, the patient must not show evidence of progressive disease while receiving Veppanu. Documented progressive disease may result in denial of continued therapy.

    • Reauthorization approval length: 12 months.
    • Continued therapy requires no evidence of progressive disease while on treatment.

    Policy Background

    Veppanu authorization is limited to treatment that is FDA-approved for the condition being treated or supported for the diagnosis in the NCCN guidelines. Initial authorization also requires documentation of an ESR1 mutation and documented intolerance, clinical failure, or contraindication to Orserdu or Inluriyo.

    Initial Therapy Criteria

    Veppanu initial authorization

    Initial authorization requires all of the following criteria.

    • FDA-approved or NCCN-supported indication

      • FDA-approved use: Requested drug is FDA-approved for the condition being treated.
      • NCCN-supported use: Treatment is supported for the diagnosis in the NCCN guidelines.
    • Specialist prescriber

      • Hematologist: Prescribed by a hematologist.
      • Oncologist: Prescribed by an oncologist.
    • ESR1 mutation: Medical record documentation of an estrogen receptor 1 (ESR1) mutation is provided.
    • Prior therapy requirement

      • Orserdu: Intolerance, clinical failure, or contraindication to Orserdu.
      • Inluriyo: Intolerance, clinical failure, or contraindication to Inluriyo.

    Continuation and Reauthorization Criteria

    Veppanu reauthorization

    Reauthorization requires that the patient does not show evidence of progressive disease while on therapy.

    No progressive disease: The patient does not show evidence of progressive disease while on therapy.

    Step Therapy Requirement

    StepPrior therapy optionsRequirement
    1Orserdu or InluriyoDocument medical record evidence of intolerance, clinical failure, or contraindication to at least one prior therapy.